Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has shared an announcement.
Firebrick Pharma has secured acceptance of a key patent in the Philippines covering the use of its Nasodine Nasal Spray and other intranasal povidone-iodine products to reduce SARS-CoV-2 viral load and provide pre-exposure prophylaxis against COVID-19. The patent, which runs to 2040 and aligns with similar protections granted in major regions including the United States, Europe and Australia, is expected to strengthen Firebrick’s commercial position as it seeks regulatory approval in the strategically important Philippine market during 2026 and builds out its Nasodine franchise globally.
The most recent analyst rating on (AU:FRE) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Firebrick Pharma Limited stock, see the AU:FRE Stock Forecast page.
More about Firebrick Pharma Limited
Firebrick Pharma Limited is an Australian pharmaceutical company focused on developing and commercialising novel formulations and uses of povidone-iodine (PVP-I) for respiratory and viral infections. Its lead product, Nasodine Nasal Spray, and follow-on Nasodine Throat Spray are already marketed in the United States, Singapore, Fiji and the South Pacific, with plans to expand the Nasodine range to up to four products and enter as many as 10 markets over the next three years, including the Philippines.
Average Trading Volume: 67,007
Technical Sentiment Signal: Sell
Current Market Cap: A$13.89M
Learn more about FRE stock on TipRanks’ Stock Analysis page.